Roivant Sciences Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Roivant Sciences Ltd.
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.
CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.